This is the authors' abstract. We don't add key points for this paper.
These guidelines are based upon two companion International Working Group on the Diabetic Foot papers: ‘A Systematic Review of the Effectiveness of Interventions in the Management of Infection in the Diabetic Foot’ and ‘Expert Opinion on the Management of Infections in the Diabetic Foot’. BAL has served as a consultant to Merck, Pfizer, Cubist, DiPexium, Johnson & Johnson. ARB was a Pfizer Visiting Professor in 2011 to the University of Washington Department of Allergy and Infectious Diseases, an educationally unrestricted programme for which funding was awarded to DAID on a peer reviewed and competitive basis. ARB received no personal financial benefit from this programme. ES has served as an investigator in the EU-CORE database study (NOVARTIS).
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Lipsky et al. (2012) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: